共 50 条
- [22] Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021 [J]. JOURNAL OF INFECTION, 2023, 87 (01) : E1 - E4
- [24] Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Pseudomonas aeruginosa Infection [J]. INFECTION AND DRUG RESISTANCE, 2022, 15 : 655 - 667
- [26] Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infection in Lung Transplant Recipients [J]. INFECTION AND DRUG RESISTANCE, 2023, 16 : 2237 - 2246
- [27] Molecular Analysis of Carbapenem and Aminoglycoside Resistance Genes in Carbapenem-Resistant Pseudomonas aeruginosa Clinical Strains: A Challenge for Tertiary Care Hospitals [J]. ANTIBIOTICS-BASEL, 2024, 13 (02):
- [30] Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant Pseudomonas aeruginosa [J]. ANTIBIOTICS-BASEL, 2022, 11 (04):